Study of WSK-IM02 for platinum-resistant recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called WSK-IM02 for people with ovarian cancer that has come back after platinum-based chemotherapy. The drug is given directly into the abdomen (intraperitoneal) and aims to slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have ovarian cancer that has returned or progressed within 6 months after finishing platinum-based chemo (like carboplatin or cisplatin).
- You have had at least one additional treatment after the cancer became resistant to platinum, and no more than 3 lines of systemic therapy in total.
- You are able to perform daily activities with some help (ECOG score 0-2).
- You have at least one measurable tumor (by scans).
- Your major organs (blood, liver, kidneys) are working well enough, and you are expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs — sacituzumab tirumotecan (which attacks cancer cells) and bevacizumab (which cuts off blood supply to tumors) — for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination helps shrink or slow the cancer.
This study tests a new investigational drug called JSKN003 for people with ovarian cancer that has stopped responding to standard chemotherapy. The goal is to see if this drug can help shrink tumors and slow down the cancer's growth.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
This trial tests IN10018 together with standard chemotherapy in people with high-grade serous ovarian (or related) cancer that has come back or progressed soon after platinum treatment. The goal is to see if adding IN10018 can improve cancer control and safety.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer (PROC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.